Cytokine profiles in acute liver injury-Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group.

Changes in levels of cytokines and chemokines have been proposed as possible biomarkers of tissue injury, including liver injury due to drugs. Recently, in acute drug-induced liver injury (DILI), we showed that 19 of 27 immune analytes were differentially expressed and that disparate patterns of imm...

Full description

Bibliographic Details
Main Authors: Herbert L Bonkovsky, Huiman X Barnhart, David M Foureau, Nury Steuerwald, William M Lee, Jiezhun Gu, Robert J Fontana, Paul J Hayashi, Naga Chalasani, Victor M Navarro, Joseph Odin, Andrew Stolz, Paul B Watkins, Jose Serrano, US Drug-Induced Liver Injury Network and the Acute Liver Failure Study Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC6201986?pdf=render
id doaj-2b7e720581cc4865b744d7229e871314
record_format Article
spelling doaj-2b7e720581cc4865b744d7229e8713142020-11-25T02:01:24ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-011310e020638910.1371/journal.pone.0206389Cytokine profiles in acute liver injury-Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group.Herbert L BonkovskyHuiman X BarnhartDavid M FoureauNury SteuerwaldWilliam M LeeJiezhun GuRobert J FontanaPaul J HayashiNaga ChalasaniVictor M NavarroJoseph OdinAndrew StolzPaul B WatkinsJose SerranoUS Drug-Induced Liver Injury Network and the Acute Liver Failure Study GroupChanges in levels of cytokines and chemokines have been proposed as possible biomarkers of tissue injury, including liver injury due to drugs. Recently, in acute drug-induced liver injury (DILI), we showed that 19 of 27 immune analytes were differentially expressed and that disparate patterns of immune responses were evident. Lower values of serum albumin (< 2.8 g/dL) and lower levels of only four analytes, namely, IL-9, IL-17, PDGF-bb, and RANTES, were highly predictive of early death [accuracy = 96%]. The goals of this study were to assess levels of the same 27 immune analytes in larger numbers of subjects to learn whether the earlier findings would be confirmed in new and larger cohorts of subjects, compared with a new cohort of healthy controls. We studied 127 subjects with acute DILI enrolled into the US DILIN. We also studied 118 subjects with severe acute liver injury of diverse etiologies, enrolled into the ALF SG registry of subjects. Controls comprised 63 de-identified subjects with no history of liver disease and normal liver tests. Analytes associated with poor outcomes [death before 6 months, n = 32 of the total of 232 non-acetaminophen (Apap) subjects], were lower serum albumin [2.6 vs 3.0 g/dL] and RANTES [6,458 vs 8,999 pg/mL] but higher levels of IL-6 [41 vs 18], IL-8 [78 vs 48], and MELD scores [30 vs 24]. Similar patterns were observed for outcome of death/liver transplant within 6 months. A model that included only serum albumin < 2.8 g/dL and RANTES below its median value of 11,349 had 83% (or 81%) accuracy for predicting early death (or early death/liver transplant) in 127 subjects from DILIN. No patterns of serum immune analytes were reflective of the etiologies of acute liver failure, but there were cytokine patterns that predicted prognosis in both acute DILI and ALF.http://europepmc.org/articles/PMC6201986?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Herbert L Bonkovsky
Huiman X Barnhart
David M Foureau
Nury Steuerwald
William M Lee
Jiezhun Gu
Robert J Fontana
Paul J Hayashi
Naga Chalasani
Victor M Navarro
Joseph Odin
Andrew Stolz
Paul B Watkins
Jose Serrano
US Drug-Induced Liver Injury Network and the Acute Liver Failure Study Group
spellingShingle Herbert L Bonkovsky
Huiman X Barnhart
David M Foureau
Nury Steuerwald
William M Lee
Jiezhun Gu
Robert J Fontana
Paul J Hayashi
Naga Chalasani
Victor M Navarro
Joseph Odin
Andrew Stolz
Paul B Watkins
Jose Serrano
US Drug-Induced Liver Injury Network and the Acute Liver Failure Study Group
Cytokine profiles in acute liver injury-Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group.
PLoS ONE
author_facet Herbert L Bonkovsky
Huiman X Barnhart
David M Foureau
Nury Steuerwald
William M Lee
Jiezhun Gu
Robert J Fontana
Paul J Hayashi
Naga Chalasani
Victor M Navarro
Joseph Odin
Andrew Stolz
Paul B Watkins
Jose Serrano
US Drug-Induced Liver Injury Network and the Acute Liver Failure Study Group
author_sort Herbert L Bonkovsky
title Cytokine profiles in acute liver injury-Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group.
title_short Cytokine profiles in acute liver injury-Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group.
title_full Cytokine profiles in acute liver injury-Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group.
title_fullStr Cytokine profiles in acute liver injury-Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group.
title_full_unstemmed Cytokine profiles in acute liver injury-Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group.
title_sort cytokine profiles in acute liver injury-results from the us drug-induced liver injury network (dilin) and the acute liver failure study group.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2018-01-01
description Changes in levels of cytokines and chemokines have been proposed as possible biomarkers of tissue injury, including liver injury due to drugs. Recently, in acute drug-induced liver injury (DILI), we showed that 19 of 27 immune analytes were differentially expressed and that disparate patterns of immune responses were evident. Lower values of serum albumin (< 2.8 g/dL) and lower levels of only four analytes, namely, IL-9, IL-17, PDGF-bb, and RANTES, were highly predictive of early death [accuracy = 96%]. The goals of this study were to assess levels of the same 27 immune analytes in larger numbers of subjects to learn whether the earlier findings would be confirmed in new and larger cohorts of subjects, compared with a new cohort of healthy controls. We studied 127 subjects with acute DILI enrolled into the US DILIN. We also studied 118 subjects with severe acute liver injury of diverse etiologies, enrolled into the ALF SG registry of subjects. Controls comprised 63 de-identified subjects with no history of liver disease and normal liver tests. Analytes associated with poor outcomes [death before 6 months, n = 32 of the total of 232 non-acetaminophen (Apap) subjects], were lower serum albumin [2.6 vs 3.0 g/dL] and RANTES [6,458 vs 8,999 pg/mL] but higher levels of IL-6 [41 vs 18], IL-8 [78 vs 48], and MELD scores [30 vs 24]. Similar patterns were observed for outcome of death/liver transplant within 6 months. A model that included only serum albumin < 2.8 g/dL and RANTES below its median value of 11,349 had 83% (or 81%) accuracy for predicting early death (or early death/liver transplant) in 127 subjects from DILIN. No patterns of serum immune analytes were reflective of the etiologies of acute liver failure, but there were cytokine patterns that predicted prognosis in both acute DILI and ALF.
url http://europepmc.org/articles/PMC6201986?pdf=render
work_keys_str_mv AT herbertlbonkovsky cytokineprofilesinacuteliverinjuryresultsfromtheusdruginducedliverinjurynetworkdilinandtheacuteliverfailurestudygroup
AT huimanxbarnhart cytokineprofilesinacuteliverinjuryresultsfromtheusdruginducedliverinjurynetworkdilinandtheacuteliverfailurestudygroup
AT davidmfoureau cytokineprofilesinacuteliverinjuryresultsfromtheusdruginducedliverinjurynetworkdilinandtheacuteliverfailurestudygroup
AT nurysteuerwald cytokineprofilesinacuteliverinjuryresultsfromtheusdruginducedliverinjurynetworkdilinandtheacuteliverfailurestudygroup
AT williammlee cytokineprofilesinacuteliverinjuryresultsfromtheusdruginducedliverinjurynetworkdilinandtheacuteliverfailurestudygroup
AT jiezhungu cytokineprofilesinacuteliverinjuryresultsfromtheusdruginducedliverinjurynetworkdilinandtheacuteliverfailurestudygroup
AT robertjfontana cytokineprofilesinacuteliverinjuryresultsfromtheusdruginducedliverinjurynetworkdilinandtheacuteliverfailurestudygroup
AT pauljhayashi cytokineprofilesinacuteliverinjuryresultsfromtheusdruginducedliverinjurynetworkdilinandtheacuteliverfailurestudygroup
AT nagachalasani cytokineprofilesinacuteliverinjuryresultsfromtheusdruginducedliverinjurynetworkdilinandtheacuteliverfailurestudygroup
AT victormnavarro cytokineprofilesinacuteliverinjuryresultsfromtheusdruginducedliverinjurynetworkdilinandtheacuteliverfailurestudygroup
AT josephodin cytokineprofilesinacuteliverinjuryresultsfromtheusdruginducedliverinjurynetworkdilinandtheacuteliverfailurestudygroup
AT andrewstolz cytokineprofilesinacuteliverinjuryresultsfromtheusdruginducedliverinjurynetworkdilinandtheacuteliverfailurestudygroup
AT paulbwatkins cytokineprofilesinacuteliverinjuryresultsfromtheusdruginducedliverinjurynetworkdilinandtheacuteliverfailurestudygroup
AT joseserrano cytokineprofilesinacuteliverinjuryresultsfromtheusdruginducedliverinjurynetworkdilinandtheacuteliverfailurestudygroup
AT usdruginducedliverinjurynetworkandtheacuteliverfailurestudygroup cytokineprofilesinacuteliverinjuryresultsfromtheusdruginducedliverinjurynetworkdilinandtheacuteliverfailurestudygroup
_version_ 1724957197326090240